Publication date: Sep 05, 2024
Diabetes mellitus (DM) is associated with severe outcomes of coronavirus disease (COVID-19), including death. COVID-19 vaccination is crucial for preventing infection and severe disease in the general population, but most importantly, among high-risk populations such as persons with DM. However, while COVID-19 vaccination uptake in the general population is regularly tracked, information on vaccination behavior specific to persons with DM is scarce. This study aimed to identify factors associated with the uptake of full COVID-19 vaccination among persons living with DM at Kiruddu National Referral Hospital (KRH). We employed a cross-sectional study design and administered a structured questionnaire on a systematically selected random sample of 340 people with DM attending Kiruddu National Referral Hospital from March 08 to May 25, 2023. We used a Modified Poisson Regression model to identify the factors associated with full COVID-19 vaccination and present adjusted prevalence ratios, along with their 95% confidence intervals. Full COVID-19 vaccination in this study was defined as having completed the last dose in the primary series of a COVID-19 vaccine. We administered the questionnaire to 340 participants, with 75% (255 of 340) being female. The mean age of the participants was 52 years (+/- 12 years) and their median duration with diabetes mellitus was 5 years (+/- 7. 3 years). Overall, 195 out of 340 participants (57. 35%, 95% CI: 52-63%) completed the last dose in the primary series of a COVID-19 vaccine. The likelihood of receiving full vaccination was higher when a health provider advised one to receive a vaccine (aPR = 1. 91, 95% CI: 1. 20-3. 02), when one reported having a comorbidity (aPR = 1. 26, 95% CI: 1. 06-1. 53), and when one had a strong perceived benefit of vaccination (aPR = 1. 76, 95% CI: 1. 23-2. 53). However, having a strong perceived barrier to vaccination was negatively associated with the likelihood of being fully vaccinated (aPR = 0. 71, 95% CI: 0. 60-0. 84). The uptake of COVID-19 vaccines among persons with DM at KRH is low, with only 57% having a full COVID-19 vaccination status. This underscores the progress in meeting the WHO recommendation of having a 100% COVID-19 vaccination uptake among people with underlying health conditions, including diabetes mellitus. At the policy level, the Ugandan Ministry of Health (MoH) may implement a provider-initiated vaccination strategy where healthcare providers who attend to DM patients during their routine clinic visits initiate the idea of vaccinating, sensitize, and spearhead myth-bursting around COVID-19 vaccines.
Open Access PDF
Concepts | Keywords |
---|---|
Death | COVID-19 |
Diabetes | Diabetes mellitus |
Regularly | Uganda |
Ugandan | Vaccination |
Vaccination |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 |
disease | MESH | diabetes mellitus |
pathway | KEGG | Coronavirus disease |
disease | MESH | death |
disease | MESH | infection |
disease | MESH | comorbidity |
disease | MESH | Long Covid |
pathway | REACTOME | Reproduction |
drug | DRUGBANK | Coenzyme M |
drug | DRUGBANK | Stavudine |
disease | MESH | complications |
disease | MESH | obesity |
drug | DRUGBANK | Vorinostat |
drug | DRUGBANK | Ranitidine |
drug | DRUGBANK | Pentaerythritol tetranitrate |
drug | DRUGBANK | Hexocyclium |
disease | MESH | educational level |
disease | MESH | marital status |
disease | IDO | susceptibility |
disease | MESH | hypertension |
disease | MESH | chronic illnesses |
drug | DRUGBANK | Hydroxyethyl Starch |
disease | IDO | country |
drug | DRUGBANK | Trestolone |
drug | DRUGBANK | Etoperidone |
disease | MESH | Hyperglycemia |
disease | MESH | Mucormycosis |
disease | MESH | emergencies |
drug | DRUGBANK | Delorazepam |